美股生物科技股大幅反弹，降息预期升温，标普生物科技 ETF（159502）投资机遇凸显

Group 1 - The core viewpoint of the news is that the biotechnology sector in the US is experiencing a strong rebound, with significant gains in major biotech stocks after a period of decline, indicating a recovery in market sentiment and capital inflow [1] - The Shenzhen Component Index fell by 0.52% and the ChiNext Index dropped by 0.79%, while specific stocks like Revolution Medicines Inc surged over 28%, indicating a divergence in performance within the market [1] - The S&P Biotechnology ETF (159502) rose by 2.38%, with a trading volume of 0.57 billion yuan and a turnover rate of 2.42%, reflecting increased investor interest in the biotech sector [1] Group 2 - The S&P Biotechnology ETF (159502) tracks the S&P Biotechnology Select Industry Index, covering high-quality companies in the global biotechnology sector, making it suitable for both retail and professional investors [2] - The management and custody fees for the S&P Biotechnology ETF (159502) are 0.60% per year, which positions it as a long-term investment tool while also catering to the needs of active traders [2] - Despite the positive trends, the sector may face short-term pressure until an official interest rate cut occurs, highlighting the need for investors to remain cautious about potential downside risks [2]